MCM7和CDC6蛋白表达与肝细胞癌病理特征的相关性  

Correlation between MCM7 and CDC6 protein expression and pathological features of hepatocellular carcinoma

作　　者：牛广旭[1] 贾如江[2] 宋晓明[1] 郑神英[1] 王朝辉[1] NIU Guangxu;JIA Rujiang;SONG Xiaoming;ZHENG Shenying;WANG Chaohui(Department of Pathology,Handan Central Hospital,Handan 056001,Hebei,China;No.1 Department of General Surgery,Handan Central Hospital,Handan 056001,Hebei,China)

机构地区：[1]邯郸市中心医院病理科,056001 [2]邯郸市中心医院普外一科,056001

出　　处：《贵州医科大学学报》2023年第10期1220-1225,共6页Journal of Guizhou Medical University

基　　金：河北省医学研究重点课题(20170227)。

摘　　要：目的探讨微染色体维持蛋白7(MCM7)和细胞分裂周期蛋白6(CDC6)与肝细胞癌病理特征的相关性。方法选取68例原发性肝细胞癌患者,分别取癌组织和癌旁组织,采用免疫组化染色(SP)法检查MCM7和CDC6表达,比较癌组织及癌旁组织中MCM7阳性检出率及CDC6高表达占比;分析不同临床病理特征的肝细胞癌患者MCM7阳性占比及CDC6高表达占比,采取多因素logistics回归分析MCM7阳性、CDC6高表达的危险因素;3年院外随访,记录癌组织MCM7阳性及CDC6高表达患者术后3年存活率。结果癌组织内MCM7阳性检出率及CDC6高表达占比高于癌旁正常组织,差异有统计学意义(P<0.05);不同性别、年龄及乙肝抗原(HBsAg)阳性患者的MCM7阳性检出率及CDC6高表达占比差异无统计学意义(P>0.05);肿瘤直径≥5 cm、肿瘤淋巴结转移(TNM)分期Ⅲ~Ⅳ期、分化程度低分化、血清甲胎蛋白(AFP)≥400μg/L、有卫星结节患者的MCM7阳性检出率及CDC6高表达占比较高,差异有统计学意义(P<0.05);肿瘤直径≥5 cm、TNM分期Ⅲ~Ⅳ期、低分化、HBsAg阳性、血清AFP≥400μg/L、有卫星结节是MCM7阳性和CDC6高表达的危险因素(P<0.05);所有患者均获得3年院外随访,3年死亡率38.24%(26/68),存活率61.76%(42/68);MCM7阳性原发性肝癌患者死亡率44.00%(22/50)、存活率56.00%(28/50),MCM7阴性患者死亡率22.22%(4/18)、存活率83.05%(14/18),Kaplan-Meier生存分析显示癌组织MCM7阳性检出率越高患者存活率越低(P<0.05));CDC6高表达原发性肝癌患者死亡率50.00%(20/40)、存活率50.00%(20/40),CDC6低表达患者死亡率21.43%(6/28)、存活率78.57%(22/28),Kaplan-Meier生存分析显示癌组织CDC6表达越高患者存活率越低(P<0.05)。结论原发性肝细胞癌患者癌组织内MCM7和CDC6与疾病的进展有关,癌组织MCM7阳性及CDC6高表达均会影响患者的3年存活率。Objective To investigate the correlation between microchromosome maintenance protein 7(MCM7)/cyclin 6(CDC6)and pathological features of hepatocellular carcinoma(HCC).Methods A total of 68 patients with primary hepatocellular carcinoma were selected.The expression levels of MCM7 and CDC6 were examined by immunohistochemistry on tumor tissues and paracancerous tissues,respectively.The positive rate of MCM7 and the proportion of CDC6 high expression in cancer tissues and paracancerous tissues were compared.To analyze the proportion of MCM7 positive and CDC6 high expression in subjects with different clinicopathological features.Multivariate logistic regression was used to analyze the risk factors of MCM7 positive and CDC6 high expression.both groups were followed up for 3 years,and the difference in 3-year survival rate of patients with MCM7 positive tumor tissue and CDC6 high expression was recorded.Results The positive rate of MCM7 and high expression of CDC6 in cancer tissues were significantly higher than those in adjacent normal tissues,and the differences were statistically significant(P<0.05).There were no significant differences in MCM7 positive rate and CDC6 high expression ratio among different genders,ages and HBsAg types(P>0.05).Patients with tumor diameter≥5 cm,TNM stageⅢ-Ⅳ,low differentiation,serum AFP≥400μg/L,and patients with satellite nodules showed higher positive rate of MCM7 and high expression of CDC6,differences were statistically significant(P<0.05).All patients were followed up for 3 years.The 3-year mortality rate was 38.24%(26/68)and the survival rate was 61.76%(42/68).Tumor diameter≥5 cm,TNM stageⅢtoⅣ,low differentiation,HBsAg positive,serum AFP≥400,satellite nodules were the risk factors of MCM7 positive and CDC6 high expression(P<0.05).The mortality rate was 44.00%(22/50)and survival rate was 56.00%(28/50)in patients with MCM7-positive primary hepatocellular carcinoma;the mortality rate was 22.22%(4/18)and survival rate was 83.05%(14/18)in patients with MCM7-negative can

关 键 词：微染色体维持蛋白7 细胞分裂周期蛋白6 原发性肝细胞癌 临床病理特征 生存率 免疫组化法 癌组织 

分 类 号：R735.1[医药卫生—肿瘤]